Table 1.
Cryopreservation Treatment | Freezing Method | Recovery Media | Survival (%) | Regrowth (%) |
---|---|---|---|---|
Control | N/A | HalfSMM | 100 ± 0 | 90 ± 10 abc |
N/A | HalfSMM + GA3 | 100 ± 0 | 96.7 ± 3.3 a | |
N/A | MSbasal | 100 ± 0 | 95 ± 2.9 ab | |
N/A | MSbasal + GA3 | 100 ± 0 | 100 ± 0 a | |
N/A | SMM | 100 ± 0 | 93.3 ± 3.3 ab | |
no LN2 | Droplet Vitrification | HalfSMM | 76.7 ± 10.9 | 60 ± 12.6 cdef |
Droplet Vitrification | HalfSMM + GA3 | 66.7 ± 9.9 | 50 ± 13.4 def | |
Droplet Vitrification | MSbasal | 75 ± 5 | 35 ± 9.6 defg | |
Cryogenic vial | MSbasal | 80 ± 11.5 | 50 ± 17.3 | |
Droplet Vitrification | MSbasal + GA3 | 85 ± 9.6 | 75 ± 5 cdef | |
Cryogenic vial | MSbasal + GA3 | 55 ± 9.6 | 55 ± 9.6 | |
Droplet Vitrification | SMM | 85 ± 9.6 | 69.2 ± 15 abcd | |
Cryogenic vial | SMM | 80 ± 8.2 | 55 ± 12.6 | |
LN2 | Droplet Vitrification | HalfSMM | 33.3 ± 6.7 | 20 ± 0 fg |
Droplet Vitrification | HalfSMM + GA3 | 43.3 ± 6.1 | 23.3 ± 3.3 fg | |
Droplet Vitrification | MSbasal | 50 ± 5.8 | 30 ± 12.9 efg | |
Cryogenic vial | MSbasal | 55 ± 20.6 | 10 ± 10 | |
Droplet Vitrification | MSbasal + GA3 | 30 ± 5.8 | 15 ± 15 fg | |
Cryogenic vial | MSbasal + GA3 | 30 ± 5.8 | 20 ± 8.2 | |
Droplet Vitrification | SMM | 30 ± 11.3 | 3.3 ± 3.3 g | |
Cryogenic vial | SMM | 65 ± 5 | 15 ± 5 |
Survival and recovery were analyzed separately. Significant data is followed by different lower-case letters (p < 0.05). Significant differences were only found between cryopreservation treatments and media interactions when the droplet-vitrification method was used.